PPAR-γ: therapeutic target for ischemic stroke

Trends in Pharmacological Sciences

Volumn 28, Issue 5, 2007, Pages 244-249

  Culman, Juraj ^a   Zhao, Yi ^a   Gohlke, Peter ^a   Herdegen, Thomas ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DICHLOROBENZYL) 2 METHYL N PENTYLSULFONYL 3H BENZIMIDAZOLE 5 CARBOXAMID; 3 CHLORO 4 [3 (3 PHENYL 7 PROPYLBENZOFURAN 6 YLOXY)PROPYLTHIO]PHENYL ACETIC ACID; L 796449; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHENYLACETIC ACID DERIVATIVE; PIOGLITAZONE; PROSTAGLANDIN J2; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; ATHEROSCLEROSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; IMMUNITY; INFLAMMATION; LIPID METABOLISM; MICROGLIA; NERVE CELL; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; HYPOGLYCEMIC AGENTS; MICROGLIA; NEURONS; NEUROPROTECTIVE AGENTS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 34247507589     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.03.004     Document Type: Review

References (58)

1. Adams Jr. H.P., et al. Guidelines for the early management of patients with ischemic stroke. A scientific statement from the Stroke Council of the American Stroke Association. Stroke 34 (2003) 1056-1083
2. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J. Cereb. Blood Flow Metab. 26 (2006) 1465-1478
3. Green A.R., and Shuaib A. Therapeutic strategies for the treatment of stroke. Drug Discov. Today 11 (2006) 681-693
4. Armoni M., et al. FOXO1 represses peroxisome proliferator-activated receptor-γ1 and -γ2 gene promoters in primary adipocytes. A novel paradigm to increase insulin sensitivity. J. Biol. Chem. 281 (2006) 19881-19891
5. Fajas L., et al. The organization, promoter analysis, and expression of the human PPARγ gene. J. Biol. Chem. 272 (1997) 18779-18789
6. Blaschke F., et al. Obesity, peroxisome proliferator-activated receptor, and atherosclerosis in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 28-40
7. Berger J.P., et al. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol. Sci. 26 (2005) 244-251
8. Verges B. Clinical interest of PPARs ligands. Diabetes Metab. 30 (2004) 7-12
9. Kersten S., et al. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
10. Delerive P., et al. Peroxisome proliferator-activated receptors in inflammation control. J. Endocrinol. 169 (2001) 453-459
11. Chinetti G., et al. Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm. Res. 49 (2000) 497-505
12. Bordet R. PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem. Soc. Trans. 34 (2006) 1341-1346
13. Roses A.D., et al. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J. 7 (2007) 10-28
14. Lee J.M., et al. Brain tissue response to ischemia. J. Clin. Invest. 106 (2000) 723-731
15. Dirnagl U., et al. Pathophysiology of ischemic stroke. Trends Neurosci. 22 (1999) 391-397
16. Graham S.H., and Hickey R.W. Cyclooxygenases in central nervous system. A special role of cyclooxygenase 2 in neuronal cell death. Arch. Neurol. 60 (2003) 628-630
17. Mattson M.P., et al. Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res. 301 (2000) 173-187
18. Iadecola C., and Alexander M. Cerebral ischemia and inflammation. Curr. Opin. Neurol. 14 (2001) 89-94
19. Mabuchi T., et al. Contribution of microglia/macrophages to expansion of infarction and response of oligodendrocytes after focal cerebral ischemia in rats. Stroke 31 (2000) 1735-1743
20. Pantoni L., et al. Cytokines and cell adhesion molecules in cerebral ischemia. Experimental bases and therapeutic perspectives. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 503-513
21. Wang Q., et al. The inflammatory response in stroke. J. Neuroimmunol. 84 (2007) 53-68
22. 2 protects brain from ischemia-reperfusion injury. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 481-487
23. Victor N.A., et al. Altered PPARγ expression and activation after transient focal ischemia in rats. Eur. J. Neurosci. 24 (2006) 1653-1663
24. Zhao Y., et al. The intracerebral application of the PPARγ-ligand pioglitazone confers neuroprotection against focal ischemia in the rat brain. Eur. J. Neurosci. 22 (2005) 278-282
25. Ou Z., et al. Neuronal expression of peroxisome proliferator-activated receptor-γ (PPARγ) and 15d-prostaglandin J2-mediated protection of brain after experimental ischemia in rat. Brain Res. 1096 (2006) 196-203
26. Zhao Y., et al. Activation of cerebral peroxisome proliferator-actiavted receptors γ promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J. 20 (2006) 1162-1175
27. Luo Y., et al. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-γ agonist rosiglitazone. J. Neurochem. 97 (2006) 435-448
28. Bernardo A., and Minghetti L. PPAR-γ agonists as regulators of microglial activation and brain inflammation. Curr. Pharm. Des. 12 (2006) 93-109
29. Collino M., et al. Modulation of the oxidative stress and inflammatory response by PPAR-γ agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 530 (2006) 70-80
30. Sundararajan S., et al. Peroxisome proliferator-activated receptor-γ ligands reduce inflammation and infarction size in transient focal ischemia. Neuroscience 130 (2005) 685-696
31. Shimazu T., et al. A peroxisome proliferator-activated receptor-γ agonist reduces infarct size in transient but not in permanent ischemia. Stroke 36 (2005) 353-359
32. Pereira M.P., et al. The nonthiazolidinedione PPARγ agonist L-796,449 is neuroprotective in experimental stroke. J. Neuropathol. Exp. Neurol. 64 (2005) 797-805
33. Chu K., et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia. Brain Res. 1093 (2006) 208-218
34. Dormandy J.A., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
35. Calabró P., et al. Inhibition of tumor-necrosis-factor α induced endothelial cell activation by a new class of PPAR-γ agonists. J. Vasc. Res. 42 (2005) 509-516
36. Sasaki M., et al. Troglitazone, a PPAR-γ activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-α. BMC Physiol. 5 (2005) 3
37. Luna-Medina R., et al. Regulation of inflammatory response in neural cells in vitro by thiadiazolidinones derivates through peroxisome proliferator-activated receptor γ activation. J. Biol. Chem. 280 (2005) 21453-21462
38. Heneka M.T., et al. Peroxisome proliferator-activated receptor γ agonists protect cerebellar granule cells from cytokine-induced apoptotic cell death by inhibition of inducible nitric oxide synthase. J. Neuroimmunol. 100 (1999) 156-168
39. Aoun P., et al. Role of PPAR-γ ligands in neuroprotection. Invest. Ophthalmol. Vis. Sci. 44 (2003) 2999-3004
40. Uryu S., et al. Troglitazone inhibits both post-glutamate neurotoxicity and low-potassium-induced apoptosis in cerebellar granule neurons. Brain Res. 924 (2002) 229-236
41. Zhao X., et al. Peroxisome-proliferator-activated receptor-γ (PPARγ) activation protects neurons from NMDA excitotoxicity. Brain Res. 1073-1074 (2006) 460-469
42. Hossmann K.-A. Pathophysiology and therapy of experimental stroke. Cell Mol. Neurobiol. 26 (2006) 1051-1081
43. Kim E.J., et al. Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. Brain Res. 941 (2002) 1-10
44. Nishijima C., et al. Survival activity of troglitazone in rat motoneurones. J. Neurochem. 76 (2001) 383-390
45. Fuenzalida K.M., et al. Peroxisome proliferator-activated receptor γ is a novel target of the nerve growth factor signalling pathway in PC12 cells. J. Biol. Chem. 280 (2005) 9604-9609
46. 2. Mol. Pharmacol. 63 (2003) 607-616
47. 2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells. Biochem. Biophys. Res. Commun. 258 (1999) 50-53
48. Benkirane K., et al. Peroxisome proliferator-activated receptor γ regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo. Hypertension 47 (2006) 102-108
49. Martin B., et al. Caloric restriction and intermittent fasting: two potential diets for successful brain aging. Ageing Res. Rev. 5 (2006) 332-353
50. 2 on rat cultured cerebellar granule cells. J. Neurosci. Res. 72 (2003) 747-755
51. 2, a specific ligand for peroxisome proliferator-activated receptor-γ induces neuronal apoptosis. Neuroreport 12 (2001) 839-843
52. 2: the endogenous electrophile that induces neuronal apoptosis. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 7367-7372
53. Belcher G., et al. Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes. Diabetes Res. Clin. Pract. 70 (2005) 53-62
54. Diamant M., and Heine R.J. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs 63 (2003) 1373-1405
55. Thal S.C., et al. New cerebral protection strategies. Curr. Opin. Anaesthesiol. 18 (2005) 490-495
56. Johnston K.C., and Mayer S.A. Blood pressure reduction in ischemic stroke: a two-edged sword?. Neurology 61 (2003) 1030-1031
57. Koziol J.A., and Feng A. On the analysis and interpretation of outcome measures in stroke clinical trials. Lessons from the SAINT I study of NXY-059 for acute ischemic stroke. Stroke 37 (2006) 2644-2647
58. Lee J., and Reding M. Effects of thiazolidinediones on stroke recovery: a case-matched controlled study. Neurochem. Res. 32 (2007) 635-638